Hjem › Livmoderslimhindekræft
Livmoderslimhindekræft kliniske forsøg rekrutterer i USA
168 studier for Livmoderslimhindekræft rekrutterer deltagere på steder over hele USA.
Byer med flest studier
- Houston, TX68 studier
- New York City, NY52 studier
- Boston, MA50 studier
- Arlington, VA39 studier
- Nashville, TN38 studier
- Los Angeles, CA34 studier
- St. Louis, MO29 studier
- Philadelphia, PA28 studier
- San Antonio, TX27 studier
- Queens, NY25 studier
- Columbus, OH25 studier
- Chicago, IL25 studier
- Oklahoma City, OK25 studier
- Dallas, TX24 studier
- Portland, OR24 studier
- Pittsburgh, PA23 studier
- Detroit, MI21 studier
- Cleveland, OH20 studier
- Rochester, MN20 studier
- Edison, NJ19 studier
- Washington, DC18 studier
- Minneapolis, MN18 studier
- Grand Rapids, MI18 studier
- Orlando, FL17 studier
- Atlanta, GA17 studier
- Seattle, WA17 studier
- Baldwin Park, CA17 studier
- Durham, NC16 studier
- Miami, FL16 studier
- Birmingham, AL16 studier
- San Diego, CA16 studier
- Austin, TX15 studier
- Denver, CO15 studier
- Tampa, FL15 studier
- Sarasota, FL15 studier
- New Haven, CT14 studier
- Providence, RI14 studier
- Salt Lake City, UT14 studier
- Indianapolis, IN14 studier
- Aurora, CO14 studier
Efter delstat
- Alabama19 studier
- Alaska4 studier
- Arizona22 studier
- Arkansas12 studier
- Californien73 studier
- Colorado30 studier
- Connecticut20 studier
- Delaware4 studier
- District of Columbia10 studier
- Florida65 studier
- Georgia24 studier
- Hawaii3 studier
- Idaho4 studier
- Illinois38 studier
- Indiana19 studier
- Iowa10 studier
- Kansas5 studier
- Kentucky10 studier
- Louisiana15 studier
- Maine7 studier
- Maryland22 studier
- Massachusetts53 studier
- Michigan43 studier
- Minnesota39 studier
- Mississippi5 studier
- Missouri31 studier
- Montana5 studier
- Nebraska10 studier
- Nevada8 studier
- New Jersey32 studier
- New Mexico13 studier
- New York69 studier
- North Carolina31 studier
- North Dakota6 studier
- Ohio50 studier
- Oklahoma28 studier
- Oregon27 studier
- Pennsylvania42 studier
- Rhode Island14 studier
- South Carolina9 studier
- South Dakota11 studier
- Tennessee41 studier
- Texas91 studier
- Utah25 studier
- Virginia51 studier
- Washington20 studier
- West Virginia4 studier
- Wisconsin24 studier
Nyligt opdaterede studier
Officiel studietekst (engelsk)
Tirzepatide in Obesity-Driven Endometrial Cancer
RekruttererTidlig fase 1
Alder 18 og opefter · Kvinder · Opdateret 2. okt. 2026 · NCT07065552Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RekruttererFase 2
Alle aldre · Alle køn · Opdateret 2. okt. 2026 · NCT05564377Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
RekruttererFase 1
Alder 18 og opefter · Kvinder · Opdateret 2. okt. 2026 · NCT05950464The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT04585750Distance-Based Exercise to Preserve Function and Prevent Disability
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT07059884A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
RekruttererFase 3
Alder 18 og opefter · Kvinder · Opdateret 2. okt. 2026 · NCT07286331A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06270706Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
RekruttererFase 3
Alder 18 og opefter · Kvinder · Opdateret 2. okt. 2026 · NCT07198074A Phase 1 Study of the Safety and Tolerability of CTX-10726
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT07419841Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RekruttererFase 2
Alder 18 til 72 · Alle køn · Opdateret 2. okt. 2026 · NCT01174121A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06760819A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RekruttererFase 1
Alder 19 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06586957A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06172478177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT07189871The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07285044A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07814248Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
RekruttererObservationsstudie
Alder 18 og opefter · Kvinder · Opdateret 29. sep. 2026 · NCT05051722Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
RekruttererFase 2
Alder 18 og opefter · Kvinder · Opdateret 28. sep. 2026 · NCT05112601Study of AVZO-021 in Patients With Advanced Solid Tumors
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05867251DESTINY-PANTUMOUR04
RekruttererObservationsstudie
Alder 18 til 130 · Alle køn · Opdateret 25. sep. 2026 · NCT07124000Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06218914ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
Rekrutterer
Alder 18 og opefter · Kvinder · Opdateret 25. sep. 2026 · NCT07270666Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
RekruttererFase 1/2
Alder 18 og opefter · Kvinder · Opdateret 25. sep. 2026 · NCT03564340Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance
RekruttererFase 2
Alder 18 og opefter · Kvinder · Opdateret 24. sep. 2026 · NCT07594015A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
RekruttererFase 1/2
Alder 18 og opefter · Kvinder · Opdateret 24. sep. 2026 · NCT04590326Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.